Google Chrome
Safari
Firefox
Edge
Search
Press Clipping / Oct 27, 2025
Hovione Completes Initial $100M Investment Cycle to Expand U.S. Operations at New Jersey Manufacturing Site
Innovations in Pharmaceutical Technology, IPT Online, 27 October 2025
News / Sep 17, 2021
World Patient Safety Day 2021
Safety First, Quality Always: We are continuously improving the safety of our operations with the patient’s safety in mind.
Press Release / Nov 29, 2023
Hovione expands nasal drug delivery capabilities with the development of nasal powder delivery device technology in collaboration with IDC
Hovione, the specialist integrated CDMO, just announced an expansion of its nasal drug delivery capabilities with the addition of a family of innovative nasal powder delivery devices developed in partnership with IDC.
Press Release / Mar 19, 2018
Hovione reports on recent capacity expansion and future plans to support growth
Hovione reported today recent capacity expansion and future plans in its sites in Portugal, Ireland and New Jersey.
Press Release / Mar 17, 2021
Hovione completes its Phase 2 clinical trial of the first minocycline ophthalmic
Showing promise in Dry Eye Disease associated with Inflamed Meibomian Gland Dysfunction
Dispersome®
Make your drug soluble with Dispersome® technology. Dispersome® is a solubility enhancement technology that relies on an innovative and naturally occurring excipient to develop amorphous solid dispersions with high drug loading and high bioavailability.
Press Release / Sep 19, 2024
Hovione and iBET Announce the Establishment of ViSync® Technologies: A Venture in Cell and Gene Therapy Solutions
Commitment to partnership and joint innovation for cell and gene therapies
Press Release / May 04, 2020
Hovione Announces the Appointment of Jean-Luc Herbeaux as Chief Operating Officer
Effective May 1st, 2020